The TOP 2301 (NCT06385262) phase II trial is looking at combining a PCSK9 inhibitor (alirocumab) with chemotherapy and the PD-1 inhibitor cemiplimab in patients with stage IB-IIIA NSCLC. The gene discussed is PCSK9; the disease is non-small cell lung carcinoma.